Literature DB >> 15761501

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.

Rosa Marina Melillo1, Maria Domenica Castellone, Valentina Guarino, Valentina De Falco, Anna Maria Cirafici, Giuliana Salvatore, Fiorina Caiazzo, Fulvio Basolo, Riccardo Giannini, Mogens Kruhoffer, Torben Orntoft, Alfredo Fusco, Massimo Santoro.   

Abstract

In papillary thyroid carcinomas (PTCs), rearrangements of the RET receptor (RET/PTC) and activating mutations in the BRAF or RAS oncogenes are mutually exclusive. Here we show that the 3 proteins function along a linear oncogenic signaling cascade in which RET/PTC induces RAS-dependent BRAF activation and RAS- and BRAF-dependent ERK activation. Adoptive activation of the RET/PTC-RAS-BRAF axis induced cell proliferation and Matrigel invasion of thyroid follicular cells. Gene expression profiling revealed that the 3 oncogenes activate a common transcriptional program in thyroid cells that includes upregulation of the CXCL1 and CXCL10 chemokines, which in turn stimulate proliferation and invasion. Thus, motile and mitogenic properties are intrinsic to transformed thyroid cells and are governed by an epistatic oncogenic signaling cascade.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15761501      PMCID: PMC1062891          DOI: 10.1172/JCI22758

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  siRNA Selection Server: an automated siRNA oligonucleotide prediction server.

Authors:  Bingbing Yuan; Robert Latek; Markus Hossbach; Thomas Tuschl; Fran Lewitter
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

2.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

Authors:  Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

3.  One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes.

Authors:  A Fusco; M T Berlingieri; P P Di Fiore; G Portella; M Grieco; G Vecchio
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

4.  The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line.

Authors:  M Santoro; R M Melillo; M Grieco; M T Berlingieri; G Vecchio; A Fusco
Journal:  Cell Growth Differ       Date:  1993-02

5.  Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

Authors:  M Santoro; F Carlomagno; I D Hay; M A Herrmann; M Grieco; R Melillo; M A Pierotti; I Bongarzone; G Della Porta; N Berger
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

6.  Tyrosine 981, a novel ret autophosphorylation site, binds c-Src to mediate neuronal survival.

Authors:  Mario Encinas; Robert J Crowder; Jeffrey Milbrandt; Eugene M Johnson
Journal:  J Biol Chem       Date:  2004-02-06       Impact factor: 5.157

Review 7.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

8.  Identification of RET autophosphorylation sites by mass spectrometry.

Authors:  Yoshiyuki Kawamoto; Kozue Takeda; Yusuke Okuno; Yoshinori Yamakawa; Yasutomo Ito; Ryo Taguchi; Masashi Kato; Haruhiko Suzuki; Masahide Takahashi; Izumi Nakashima
Journal:  J Biol Chem       Date:  2004-01-06       Impact factor: 5.157

9.  Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes.

Authors:  Maria Domenica Castellone; Anna Maria Cirafici; Gabriella De Vita; Valentina De Falco; Luca Malorni; Giovanni Tallini; James A Fagin; Alfredo Fusco; Rosa Marina Melillo; Massimo Santoro
Journal:  Oncogene       Date:  2003-01-16       Impact factor: 9.867

10.  Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells.

Authors:  Maria Domenica Castellone; Angela Celetti; Valentina Guarino; Anna Maria Cirafici; Fulvio Basolo; Riccardo Giannini; Enzo Medico; Mogens Kruhoffer; Torben F Orntoft; Francesco Curcio; Alfredo Fusco; Rosa Marina Melillo; Massimo Santoro
Journal:  Oncogene       Date:  2004-03-18       Impact factor: 9.867

View more
  104 in total

1.  Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.

Authors:  Maria Grazia Borrello; Luisella Alberti; Andrew Fischer; Debora Degl'innocenti; Cristina Ferrario; Manuela Gariboldi; Federica Marchesi; Paola Allavena; Angela Greco; Paola Collini; Silvana Pilotti; Giuliana Cassinelli; Paola Bressan; Laura Fugazzola; Alberto Mantovani; Marco A Pierotti
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

2.  Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription.

Authors:  Laura Casalino; Latifa Bakiri; Francesco Talotta; Jonathan B Weitzman; Alfredo Fusco; Moshe Yaniv; Pasquale Verde
Journal:  EMBO J       Date:  2007-03-08       Impact factor: 11.598

3.  Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.

Authors:  Ying C Henderson; Soon-Hyun Ahn; Ya'an Kang; Gary L Clayman
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

4.  Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.

Authors:  Gisele Oler; Cléber P Camacho; Flávio C Hojaij; Pedro Michaluart; Gregory J Riggins; Janete M Cerutti
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

5.  Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population.

Authors:  Ryan J Gertz; Yuri Nikiforov; William Rehrauer; Lee McDaniel; Ricardo V Lloyd
Journal:  Arch Pathol Lab Med       Date:  2016-02       Impact factor: 5.534

Review 6.  Thyroid Autoimmunity and Thyroid Cancer: Review Focused on Cytological Studies.

Authors:  Francesco Boi; Fabiana Pani; Stefano Mariotti
Journal:  Eur Thyroid J       Date:  2017-04-24

7.  Effects of let-7 microRNA on Cell Growth and Differentiation of Papillary Thyroid Cancer.

Authors:  Júlio Cezar Marques Ricarte-Filho; Cesar Seigi Fuziwara; Alex Shimura Yamashita; Eloiza Rezende; Marley Januário da-Silva; Edna Teruko Kimura
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

Review 8.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

9.  BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

Authors:  Rebecca Leboeuf; Jacqueline E Baumgartner; Miriam Benezra; Roberta Malaguarnera; David Solit; Christine A Pratilas; Neal Rosen; Jeffrey A Knauf; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

Review 10.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.